TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Swedish cohort study of women aged 70 found that longer reproductive lifespan and reported menopausal hormone therapy use were associated with some more favorable brain MRI measures. The observational findings do not show that estrogen exposure caused the differences or that hormone therapy prevents dementia.
A Swedish study of 352 cognitively unimpaired women found that a longer reproductive lifespan and use of menopausal hormone therapy were associated with lower burden of some brain blood-vessel abnormalities on MRI. The results, reported in Neurology, describe associations rather than proof that estrogen exposure protects the brain or prevents dementia.
Researchers led by Anna Marseglia of the Karolinska Institutet examined women in the 1944 Gothenburg H70 birth cohort. Participants had brain MRI at age 70; 286 returned for an examination five years later. Their average reproductive lifespan—the interval from first menstruation to menopause or ovary removal—was 37.1 years. Most participants reported oral contraceptive use, and 60.8% reported menopausal hormone therapy use.
A longer reproductive span was associated with 8% lower odds of having at least two signs of cerebral small vessel disease (odds ratio 0.92; 95% confidence interval 0.86-0.99). The study’s composite measure included white matter hyperintensities, lacunes, microbleeds and enlarged perivascular spaces. Menopausal hormone therapy use was associated with lower odds of greater small-vessel disease burden (OR 0.41; 95% CI 0.20-0.81) and higher white matter integrity (β=0.28; 95% CI 0.06-0.50).
Women who reported both oral contraceptive use earlier in life and menopausal hormone therapy later had the lowest observed small-vessel disease burden and the highest white matter integrity among the groups described. In APOE4 carriers, hormone therapy use was associated with greater thickness in cortical regions commonly affected by Alzheimer’s disease. About 31% of participants carried APOE4. The researchers also reported associations between longer estrogen exposure and more stable measures of cortical thickness and white matter over time.
What the MRI Associations Could Mean
The findings add brain blood-vessel measures to research on how reproductive history may relate to brain aging. Cerebral small vessel disease can be seen on brain imaging and is relevant to vascular brain health, while white matter integrity and cortical thickness are separate MRI measures. The study did not establish that the differences led to better thinking or memory: participants were cognitively unimpaired at enrollment, and their average baseline Mini-Mental State Examination score was 29.2.
The results may help researchers frame questions about hormonal exposure across a person’s life, rather than examining menopausal treatment alone. They do not show that starting hormone therapy will reduce an individual’s risk of dementia, nor do they establish that oral contraceptive use has a protective effect. Decisions about hormone treatment involve individual health factors and should not be based on this study alone.
Products Worth Considering
OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG
Withings BPM Vision Blood Pressure Monitor with Wi-Fi and Bluetooth
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
As an affiliate, we earn on qualifying purchases.
How This Fits Hormone Therapy Research
Earlier expectations that menopausal hormone therapy might protect against Alzheimer’s disease and cardiovascular disease were complicated by findings from the Women’s Health Initiative Memory Study. In 2003, that study reported an increased risk of probable dementia among women aged 65 or older taking estrogen-plus-progestin formulations. The broader Women’s Health Initiative also reported higher breast cancer and heart disease risks with combined treatment. Those findings contributed to FDA black box warnings, which the source report says the agency removed in 2026.
Use of hormone therapy among postmenopausal women in the United States fell from 26.9% in 1999 to 4.7% in 2020, according to figures cited in the report. More recent observational and autopsy research has examined possible links between estrogen-only therapy, Alzheimer’s-related brain changes and dementia diagnoses. The Swedish cohort adds evidence on MRI measures, but it does not resolve the broader debate about treatment benefits and risks.
“The lifetime risk of dementia in U.S. women exceeds that of men, and recent projections suggest that by 2060, the number of incident dementia cases in women will surpass that of men by 233,000.”
— Tracy Madsen, University of Vermont, in an accompanying editorial
Limits of the Cohort Evidence
The study was observational, so it cannot establish whether estrogen exposure caused the MRI differences. Hormone histories were reported by participants and may be affected by recall errors or misclassification. Researchers also lacked detailed information about oral contraceptive and menopausal hormone therapy use, limiting what can be concluded about timing, duration or specific formulations.
The cohort included women from one Swedish birth group who were cognitively unimpaired at age 70. The reported MRI associations do not by themselves show fewer dementia diagnoses, slower cognitive decline or the same pattern in other populations. The source report does not provide evidence that the results apply to hormone therapy users generally or establish a treatment recommendation.
Follow-Up and Questions for Researchers
Of the 352 women examined at age 70, 286 took part in a follow-up examination five years later. Continued analysis of that cohort may help clarify how reproductive history relates to changes in brain imaging over time, but the current report does not establish what further results will be published or when.
Further research would need more detailed records of hormone exposure, broader participant groups and outcomes that track cognition and dementia as well as MRI features. Until such evidence is available, the study is best understood as a set of associations that can guide research questions, not evidence that hormone therapy prevents brain disease.
Key Questions
What did the Swedish study find?
Among 352 cognitively unimpaired women examined at age 70, longer reproductive lifespan and reported menopausal hormone therapy use were associated with lower measures of cerebral small vessel disease. Some hormone therapy associations also involved white matter integrity and cortical thickness.
Does the study show that estrogen prevents dementia?
No. The researchers reported observational associations with brain MRI measures. The study did not establish cause and effect or show that estrogen exposure prevents dementia.
How was reproductive lifespan measured?
Researchers calculated it by subtracting age at first menstruation from age at menopause or ovary removal. The cohort’s average reproductive lifespan was 37.1 years.
What are the main limitations?
Hormone use was self-reported, which may lead to recall errors or misclassification, and detailed information about treatment use was limited. The study involved a specific group of Swedish women and cannot establish that the associations apply broadly.
Should people start hormone therapy based on these findings?
No treatment recommendation follows from this study. It does not prove a dementia-prevention benefit; people considering hormone therapy should discuss personal risks and options with a qualified health professional.
Source: medpagetoday.com
